Xilio Therapeutics (XLO) Competitors $1.14 0.00 (0.00%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends XLO vs. ARTV, PROC, IKT, NLTX, HURA, ZNTL, PRQR, CRDF, CGEN, and ACRSShould you be buying Xilio Therapeutics stock or one of its competitors? The main competitors of Xilio Therapeutics include Artiva Biotherapeutics (ARTV), Procaps Group (PROC), Inhibikase Therapeutics (IKT), Neoleukin Therapeutics (NLTX), TuHURA Biosciences (HURA), Zentalis Pharmaceuticals (ZNTL), ProQR Therapeutics (PRQR), Cardiff Oncology (CRDF), Compugen (CGEN), and Aclaris Therapeutics (ACRS). These companies are all part of the "pharmaceutical products" industry. Xilio Therapeutics vs. Artiva Biotherapeutics Procaps Group Inhibikase Therapeutics Neoleukin Therapeutics TuHURA Biosciences Zentalis Pharmaceuticals ProQR Therapeutics Cardiff Oncology Compugen Aclaris Therapeutics Xilio Therapeutics (NASDAQ:XLO) and Artiva Biotherapeutics (NASDAQ:ARTV) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, media sentiment, community ranking, valuation, earnings, institutional ownership and dividends. Do institutionals and insiders believe in XLO or ARTV? 54.3% of Xilio Therapeutics shares are held by institutional investors. 5.2% of Xilio Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Do analysts rate XLO or ARTV? Xilio Therapeutics presently has a consensus price target of $4.00, indicating a potential upside of 250.88%. Artiva Biotherapeutics has a consensus price target of $21.00, indicating a potential upside of 221.59%. Given Xilio Therapeutics' higher probable upside, equities research analysts plainly believe Xilio Therapeutics is more favorable than Artiva Biotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xilio Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Artiva Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community prefer XLO or ARTV? Xilio Therapeutics received 3 more outperform votes than Artiva Biotherapeutics when rated by MarketBeat users. However, 100.00% of users gave Artiva Biotherapeutics an outperform vote while only 75.00% of users gave Xilio Therapeutics an outperform vote. CompanyUnderperformOutperformXilio TherapeuticsOutperform Votes1275.00% Underperform Votes425.00% Artiva BiotherapeuticsOutperform Votes9100.00% Underperform VotesNo Votes Does the media favor XLO or ARTV? In the previous week, Xilio Therapeutics had 2 more articles in the media than Artiva Biotherapeutics. MarketBeat recorded 2 mentions for Xilio Therapeutics and 0 mentions for Artiva Biotherapeutics. Artiva Biotherapeutics' average media sentiment score of 0.00 beat Xilio Therapeutics' score of -0.01 indicating that Artiva Biotherapeutics is being referred to more favorably in the news media. Company Overall Sentiment Xilio Therapeutics Neutral Artiva Biotherapeutics Neutral Is XLO or ARTV more profitable? Artiva Biotherapeutics' return on equity of 0.00% beat Xilio Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Xilio TherapeuticsN/A -211.50% -80.31% Artiva Biotherapeutics N/A N/A N/A Which has better valuation & earnings, XLO or ARTV? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioXilio TherapeuticsN/AN/A-$76.40M-$1.72-0.66Artiva BiotherapeuticsN/AN/AN/AN/AN/A SummaryXilio Therapeutics and Artiva Biotherapeutics tied by winning 5 of the 10 factors compared between the two stocks. Get Xilio Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for XLO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XLO vs. The Competition Export to ExcelMetricXilio TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$50.11M$6.22B$5.21B$9.14BDividend YieldN/A2.94%5.13%4.02%P/E Ratio-0.669.8789.3417.36Price / SalesN/A309.211,240.0477.11Price / CashN/A61.4443.7535.97Price / Book0.856.055.314.79Net Income-$76.40M$154.90M$122.54M$225.00M7 Day Performance3.64%-0.32%0.59%2.62%1 Month Performance-10.94%0.43%2.55%3.81%1 Year Performance67.92%3.08%25.29%20.10% Xilio Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XLOXilio Therapeutics2.9954 of 5 stars$1.14flat$4.00+250.9%+67.9%$50.11MN/A-0.6670Gap UpARTVArtiva BiotherapeuticsN/A$7.69-17.8%$21.00+173.1%N/A$186.78M$2.60M0.0081Lockup ExpirationGap UpPROCProcaps GroupN/A$1.65+3.1%N/A-60.6%$186.15M$414.10M3.175,500Positive NewsGap UpIKTInhibikase Therapeutics1.6593 of 5 stars$2.76-6.4%$6.50+135.5%+58.1%$185.45M$260,000.00-1.036Positive NewsGap DownNLTXNeoleukin TherapeuticsN/A$19.58-8.9%N/A-45.0%$184.01MN/A-6.3090High Trading VolumeHURATuHURA BiosciencesN/A$4.31-11.1%$13.00+201.6%N/A$182.25MN/A0.00N/APositive NewsZNTLZentalis Pharmaceuticals2.766 of 5 stars$2.55-7.3%$10.00+292.2%-82.6%$181.73M$40.56M-1.02160Positive NewsPRQRProQR Therapeutics2.7586 of 5 stars$2.22-8.3%$8.83+297.9%+13.9%$181.33M$17.88M-6.94180CRDFCardiff Oncology2.1519 of 5 stars$3.50-3.0%$10.33+195.2%+128.5%$178.97M$688,000.00-3.7220Positive NewsCGENCompugen2.4353 of 5 stars$2.00+21.6%$4.00+100.5%+16.0%$178.03M$59.85M99.7570Positive NewsHigh Trading VolumeACRSAclaris Therapeutics4.0051 of 5 stars$2.46-0.4%$11.00+347.2%+125.4%$175.72M$27.08M-4.7386Short Interest ↑Positive News Related Companies and Tools Related Companies ARTV Competitors PROC Competitors IKT Competitors NLTX Competitors HURA Competitors ZNTL Competitors PRQR Competitors CRDF Competitors CGEN Competitors ACRS Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:XLO) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredTrump’s Inauguration Shocker: “Move Your Cash Now”Just in the first week after Trump's win, many stocks jumped by double and even triple digits. But now he's...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xilio Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xilio Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
